The comparative study of effectiveness of influenza vaccine in cirrhotic patients, healthy individuals and inactive carriers of hepatitis B.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812103456N1

Enrollment

Registered

2010-05-25

Start date

2009-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis. Fibrosis and cirrhosis of liver

Interventions

Trivalent influenza vaccine.

Prevention

Trivalent influenza vaccine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age > 18 years old, patient with cirrhosis and inactive carrier of hepatitis B and control group of healthy individuals (health car worker) Exclusion criteria: age < 18 years old, patient with hepatic disease except cirrhosis, chronic active carrier of HBV, health care worker (with HBS Ag positive or HCV Ab positive or HIV positive)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Immunity for Influenza Viruses. Timepoint: One mounth after Vaccination. Method of measurement: With Hemaglutination and Inhibition Method.	—

Secondary

Measure	Time frame
Adverse effect of vaccination. Timepoint: One Month. Method of measurement: Observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mohamad Hosein Ari Tabarestani

Kermanshah University Medical School

htabarestani@kums.ac.ir+98 83 1426 5184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026